Search
Close this search box.

What is happening at Pivot Park?

News

Search

Categories

Mariska Koster
News

Leaders in Life Sciences – #17 Mariska Koster

In the Leaders of Life Sciences Podcast, André van de Sande talks to leaders of now and soon in the life sciences sector. We believe that there needs to be more spoken by people in the sector about themselves but also about their work. That starts with the leaders of today who are questioned about their careers and motivations. These are leaders working in the broadest corners of the industry, but they all have one thing in common: our guests all have a mission to contribute to improving health worldwide. In episode 17, our guest is: Mariska Koster, Lead Strategic Alliances at Janssen Nederland.

Read More »
Citryll
News

Press release: Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

Lonza strengthens its antibody-drug conjugates (ADCs) offering with the acquisition of Synaffix. The integration of Synaffix’s technology platform and R&D capabilities will enhance Lonza’s bioconjugates services, including payload and site-specific linker technology. The companies will expand their Center of Excellence for bioconjugate technology development, focusing on out-licensing bioconjugate technologies for various applications. The acquisition involves a cash consideration of €100 million and additional performance-based consideration. Lonza aims to provide comprehensive services for the discovery, development, and commercialization of novel ADCs, streamlining the path to clinic and market. The move reflects Lonza’s strategy of differentiating through technology and innovation.

Read More »
Brigitte Drees
News

Leaders in Life Sciences – #16 Brigitte Drees

In the Leaders of Life Sciences Podcast, André van de Sande talks to leaders of now and soon in the life sciences sector. We believe that there needs to be more spoken by people in the sector about themselves but also about their work. That starts with the leaders of today who are questioned about their careers and motivations. These are leaders working in the broadest corners of the industry, but they all have one thing in common: our guests all have a mission to contribute to improving health worldwide. In episode 16, our guest is: Brigitte Drees, CEO of Pivot Park and Pivot Park Screening Centre.

Read More »
#100yearspharmafuture
#100yearspharmafuture

#100yearspharmafuture – Pharma Future Run

The theme year #100yearspharmafuture, which focused on the 100 years anniversary of the pharmaceutical industry in Oss, will be closed sportily with a running and walking race. The starting and finish line will be at Pivot Park, while the exceptional course will take you through the heart of Oss, along the pharmaceutical companies at Moleneind.

Read More »
Sander van Deventer
News

Leaders in Life Sciences – #15 Sander van Deventer

In the Leaders of Life Sciences Podcast, André van de Sande talks to leaders of now and soon in the life sciences sector. We believe that there needs to be more spoken by people in the sector about themselves but also about their work. That starts with the leaders of today who are questioned about their careers and motivations. These are leaders working in the broadest corners of the industry, but they all have one thing in common: our guests all have a mission to contribute to improving health worldwide. In episode 15, our guest is: Sander van Deventer, Operating Partner at Forbion and CEO at VectorY.

Read More »
Press Release KNCV
News

Press release: National Chemical Landmark 2023

The Royal Netherlands Chemical Society (KNCV) will proclaim the Pharmacological Laboratory at Pivot Park in Oss a National Chemical Heritage on June 22, 2023. This building was the foundation for many chemical-pharmaceutical inventions with great social impact, including the birth control pill. Prior to the unveiling of the plaque, a lecture program on the role of this property in chemical-pharmaceutical history, the present and the future will take place. The program is open to the public at no cost; register at www.kncv.nl/nce.

Read More »
Constantijn van Oranje
News

Leaders in Life Sciences – #14 Constantijn van Oranje-Nassau

In de Leaders of Life Sciences Podcast gaat André van de Sande in gesprek met leiders van nu en straks in de life sciences sector. Wij zijn ervan overtuigd dat er meer open gesproken moet worden door mensen uit de sector over henzelf maar ook over hun werk. Dat begint bij de leiders van nu die in de podcast bevraagd worden over hun carrière en drijfveren. Het zijn leiders die allen werkzaam zijn in de breedste uithoeken van de sector, maar één ding hebben ze allemaal gemeen: onze gasten hebben allemaal een missie om bij te dragen aan het verbeteren van de gezondheid wereldwijd. Hoe doen ze dit en is hiervoor begrip? In aflevering 14 is onze gast: Constantijn van Oranje-Nassau, Special Envoy voor Techleap.nl.

Read More »
Marion Koopmans
News

Leaders in Life Sciences – #12 Marion Koopmans

In de Leaders of Life Sciences Podcast gaat André van de Sande in gesprek met leiders van nu en straks in de life sciences sector. Wij zijn ervan overtuigd dat er meer open gesproken moet worden door mensen uit de sector over henzelf maar ook over hun werk. Dat begint bij de leiders van nu die in de podcast bevraagd worden over hun carrière en drijfveren. Het zijn leiders die allen werkzaam zijn in de breedste uithoeken van de sector, maar één ding hebben ze allemaal gemeen: onze gasten hebben allemaal een missie om bij te dragen aan het verbeteren van de gezondheid wereldwijd. Hoe doen ze dit en is hiervoor begrip? In aflevering 12 is onze gast: Marion Koopmans, Virologe en Hoofd van de afdeling Viroscience aan het ErasmusMC.

Read More »
Pharming announced approval Joenja
News

Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS

Pharming Group N.V. announces that the US Food and Drug Administration (FDA) has approved Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. Joenja®, an oral, selective PI3Kδ inhibitor, is the first and only treatment approved in the US for APDS, a rare and progressive primary immunodeficiency.

Read More »
Get to know Rescop
News

Get to know: Rescop

Rescop, established in 2005 by two experienced corporate auditors from the pharmaceutical industry, offers innovative solutions for GxP regulatory compliance. Their passion for quality management software led to the founding of Rescop, which now provides a wide range of consulting services to support GxP regulated companies in establishing and maintaining compliance in a highly efficient manner. By combining consulting services with software products, Rescop offers a unique portfolio of quality management solutions suitable for businesses of all sizes and stages of maturity.

Read More »
Synaffix collaboration
News

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

Synaffix announces the expansion of their collaboration with biopharmaceutical company MacroGenics, Inc., to a value of up to $2.2B plus up to high single-digit royalties. Under this new expanded deal, MacroGenics, Inc. will pursue up to seven of the ADC programs, helping to further contribute towards the transformation of cancer treatment.

Read More »

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?

#100YEARSPHARMAFUTURE

The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.